Small Molecules — Pipeline, Approvals, Sponsors

Traditional small-molecule drugs — typically synthesised chemical entities under 1kDa, usually oral. Includes kinase inhibitors, GPCR agonists/antagonists, ion channel modulators, enzyme inhibitors.

16,881
Marketed
0
Filed
9,158
Phase 3
7,982
Phase 2
12,029
Phase 1
46,515
Total

Marketed leaders

Recent approvals (last 30 days)

No approvals in the last 30 days.

Upcoming PDUFA (next 180 days)

No upcoming PDUFA in next 180 days.

Top sponsors in this modality

  1. · 2693 small molecules
  2. GlaxoSmithKline · 792 small molecules
  3. Pfizer · 676 small molecules
  4. AstraZeneca · 605 small molecules
  5. Eli Lilly and Company · 405 small molecules
  6. Merck Sharp & Dohme LLC · 400 small molecules
  7. Sanofi · 355 small molecules
  8. Hoffmann-La Roche · 319 small molecules
  9. Bayer · 287 small molecules
  10. Bristol-Myers Squibb · 270 small molecules

Drug classes within Small Molecules

Subscribe to ongoing alerts

Push every new small molecules event into your RSS reader:

Other modalities

BiologicsMonoclonal AntibodiesAntibody-Drug ConjugatesCell TherapiesGene TherapiesGene EditingmRNA TherapeuticssiRNA TherapeuticsAntisense OligonucleotidesBispecific AntibodiesVaccines